文献速递胃肠动力与功能性疾病

随机临床试验:米沙必利对比安慰剂治疗便秘型肠易激综合征

Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.
PubMed 文献 · Aliment Pharmacol Ther · 2020-06-25

这项双盲、安慰剂对照、剂量探索研究将411例Rome IV定义的便秘型肠易激综合征(IBS-C)患者随机分配至米沙必利10、20或40 mg/d组或安慰剂组治疗12周。主要终点FDA复合应答率在各组间无剂量反应关系,但米沙必利40 mg组在更严格复合终点及自发排便频率上优于安慰剂。米沙必利安全且耐受性良好,最常见不良事件为轻度腹泻。

要点

  • 米沙必利10、20、40 mg/d组FDA复合应答率分别为13.6%、19.2%、14.9%,安慰剂组为13.6%,未见剂量反应关系。
  • 米沙必利40 mg组达到更严格复合终点(≥9/12周)的患者比例高于安慰剂组(P < 0.05)。
  • 米沙必利40 mg组第12周自发排便频率较安慰剂组显著增加(校正P < 0.001)。

核心结论

  • 米沙必利安全且耐受性良好;尽管主要终点为阴性,米沙必利40 mg可能改善更严格复合终点和自发排便频率。

研究设计与样本

  • 双盲、安慰剂对照、剂量探索研究,共411例Rome IV定义的IBS-C患者随机接受米沙必利10、20或40 mg/d或安慰剂治疗12周。

主要发现

  • FDA复合应答率:安慰剂组13.6%(14/103),10 mg组13.6%(14/103),20 mg组19.2%(20/104),40 mg组14.9%(15/101),未发现剂量反应关系。
  • 米沙必利40 mg组达到更严格复合评价(两项应答要求均满足≥9/12周)的患者比例高于安慰剂组(P < 0.05)。
  • 米沙必利40 mg组自发排便频率较安慰剂组显著增加(第12周校正P < 0.001)。
  • 最常见不良事件为轻度腹泻。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Agonists of 5-hydroxytryptamine 4 receptor are potential agents for irritable bowel syndrome with predominant constipation (IBS-C). However, only tegaserod has been approved for a very limited population in the US. AIM: To evaluate the efficacy and safety of minesapride in patients with Rome IV defined IBS-C. METHODS: A double-blind, placebo-controlled, dose-finding study was performed. Overall, 411 patients were randomised to receive minesapride at 10, 20 or 40 mg/d, or placebo for 12 weeks. The primary endpoint was Food and Drug Administration (FDA) composite endpoint (responder: a patient who reported an increase in one or more complete spontaneous bowel movements from baseline and improvement of ≥30% from baseline in weekly average of worst abdominal pain score, both in the same week for ≥6/12 weeks). RESULTS: The FDA composite responder rate was 13.6% (14/103) in the placebo group, 13.6% (14/103) in the 10 mg group, 19.2% (20/104) in the 20 mg group and 14.9% (15/101) in the 40 mg group, and no dose-response relationship was found. A greater percentage of minesapride 40 mg-treated patients than placebo-treated patients met both responder requirements for ≥9/12 weeks as the stricter composite evaluation (P < 0.05). Furthermore, minesapride 40 mg significantly increased SBM frequency compared with placebo (adjusted P < 0.001 at Week 12). The most common adverse event was mild diarrhoea. CONCLUSIONS: Minesapride was safe and well-tolerated. Although the primary endpoint was negative, minesapride 40 mg is likely to improve the stricter composite endpoint and SBM frequency. Japan Pharmaceutical Information Center Number: Japic CTI-163459.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hamatani T, Fukudo S, Nakada Y, et al. Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation. Aliment Pharmacol Ther. 2020. PMID: 32583907. doi:10.1111/apt.15907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。